BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25137041)

  • 1. Expression of STAT5, COX-2 and PIAS3 in correlation with NSCLC histhopathological features.
    Pastuszak-Lewandoska D; Domańska D; Czarnecka KH; Kordiak J; Migdalska-Sęk M; Nawrot E; Kiszałkiewicz J; Antczak A; Górski P; Brzeziańska E
    PLoS One; 2014; 9(8):e104265. PubMed ID: 25137041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoexpression analysis of selected JAK/STAT pathway molecules in patients with non- small-cell lung cancer.
    Pastuszak-Lewandoska D; Domańska-Senderowska D; Kordiak J; Antczak A; Czarnecka KH; Migdalska-Sęk M; Nawrot E; Kiszałkiewicz JM; Brzeziańska-Lasota E
    Pol Arch Intern Med; 2017 Nov; 127(11):758-764. PubMed ID: 28972958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein inhibitor of activated STAT3 expression in lung cancer.
    Kluge A; Dabir S; Vlassenbroeck I; Eisenberg R; Dowlati A
    Mol Oncol; 2011 Jun; 5(3):256-64. PubMed ID: 21497567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.
    Kluge A; Dabir S; Kern J; Nethery D; Halmos B; Ma P; Dowlati A
    Int J Cancer; 2009 Oct; 125(7):1728-34. PubMed ID: 19569236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAI-1/PIAS3/Stat3/miR-34a forms a positive feedback loop to promote EMT-mediated metastasis through Stat3 signaling in Non-small cell lung cancer.
    Lin X; Lin BW; Chen XL; Zhang BL; Xiao XJ; Shi JS; Lin JD; Chen X
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1464-1470. PubMed ID: 28988111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.
    Dagvadorj A; Tan SH; Liao Z; Xie J; Nurmi M; Alanen K; Rui H; Mirtti T; Nevalainen MT
    Int J Biochem Cell Biol; 2010 Dec; 42(12):2037-46. PubMed ID: 20854925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIAS3 expression in squamous cell lung cancer is low and predicts overall survival.
    Abbas R; McColl KS; Kresak A; Yang M; Chen Y; Fu P; Wildey G; Dowlati A
    Cancer Med; 2015 Mar; 4(3):325-32. PubMed ID: 25573684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Expression Levels of IL-4/IL-13/STAT6 Signaling Pathway Genes and SOCS3 Could Help to Differentiate the Histopathological Subtypes of Non-Small Cell Lung Carcinoma.
    Pastuszak-Lewandoska D; Domańska-Senderowska D; Antczak A; Kordiak J; Górski P; Czarnecka KH; Migdalska-Sęk M; Nawrot E; Kiszałkiewicz JM; Brzeziańska-Lasota E
    Mol Diagn Ther; 2018 Oct; 22(5):621-629. PubMed ID: 30105735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT5A and STAT5B have opposite correlations with drug response gene expression.
    Lamba V; Jia B; Liang F
    Biochem Biophys Res Commun; 2016 Oct; 479(2):117-124. PubMed ID: 27264955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival.
    Dabir S; Kluge A; Kresak A; Yang M; Fu P; Groner B; Wildey G; Dowlati A
    Clin Cancer Res; 2014 Oct; 20(19):5124-32. PubMed ID: 25124686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT5 isoforms regulate colorectal cancer cell apoptosis via reduction of mitochondrial membrane potential and generation of reactive oxygen species.
    Du W; Wang YC; Hong J; Su WY; Lin YW; Lu R; Xiong H; Fang JY
    J Cell Physiol; 2012 Jun; 227(6):2421-9. PubMed ID: 21826656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent.
    Dabir S; Kluge A; Dowlati A
    Mol Cancer Res; 2009 Nov; 7(11):1854-60. PubMed ID: 19903771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of PIAS3 an inhibitor of activated STAT3 protein in human prostate cancer].
    Gan L; Yin ZF; Li M
    Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):419-21. PubMed ID: 18581899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis.
    Wu W; Takanashi M; Borjigin N; Ohno SI; Fujita K; Hoshino S; Osaka Y; Tsuchida A; Kuroda M
    Br J Cancer; 2013 Feb; 108(3):653-61. PubMed ID: 23322197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COX-2 overexpression and -8473 T/C polymorphism in 3' UTR in non-small cell lung cancer.
    Bhat IA; Rasool R; Qasim I; Masoodi KZ; Paul SA; Bhat BA; Ganaie FA; Aziz SA; Shah ZA
    Tumour Biol; 2014 Nov; 35(11):11209-18. PubMed ID: 25113252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death.
    Borghouts C; Tittmann H; Delis N; Kirchenbauer M; Brill B; Groner B
    Mol Cancer Res; 2010 Apr; 8(4):539-53. PubMed ID: 20371673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIAS3-mediated feedback loops promote chronic colitis-associated malignant transformation.
    Ma J; Yang Y; Fu Y; Guo F; Zhang X; Xiao S; Zhu W; Huang Z; Zhang J; Chen J
    Theranostics; 2018; 8(11):3022-3037. PubMed ID: 29896300
    [No Abstract]   [Full Text] [Related]  

  • 18. [Mechanisms of EGF regulation of COX-2 through the STAT5 signaling pathway in human lung adenocarcinoma A549 cells].
    Cao S; Zhao G; Dong Q; Han J; Xin Y; Yan Y; Li J; Cui J
    Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):169-76. PubMed ID: 23601296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RARβ Promoter Methylation as an Epigenetic Mechanism of Gene Silencing in Non-small Cell Lung Cancer.
    Dutkowska A; Antczak A; Pastuszak-Lewandoska D; Migdalska-Sek M; Czarnecka KH; Górski P; Kordiak J; Nawrot E; Brzeziańska-Lasota E
    Adv Exp Med Biol; 2016; 878():29-38. PubMed ID: 26453065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas.
    Zhan P; Shen XK; Qian Q; Zhu JP; Zhang Y; Xie HY; Xu CH; Hao KK; Hu W; Xia N; Lu GJ; Yu LK
    Med Oncol; 2012 Jun; 29(2):648-55. PubMed ID: 21519871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.